ZA956995B - Methods of reducing scarring in wound healing. - Google Patents

Methods of reducing scarring in wound healing.

Info

Publication number
ZA956995B
ZA956995B ZA9506995A ZA956995A ZA956995B ZA 956995 B ZA956995 B ZA 956995B ZA 9506995 A ZA9506995 A ZA 9506995A ZA 956995 A ZA956995 A ZA 956995A ZA 956995 B ZA956995 B ZA 956995B
Authority
ZA
South Africa
Prior art keywords
methods
wound healing
reducing scarring
scarring
reducing
Prior art date
Application number
ZA9506995A
Other languages
English (en)
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA956995B publication Critical patent/ZA956995B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9506995A 1994-08-22 1995-08-21 Methods of reducing scarring in wound healing. ZA956995B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/293,851 US5550151A (en) 1994-08-22 1994-08-22 Methods of reducing scarring in wound healing

Publications (1)

Publication Number Publication Date
ZA956995B true ZA956995B (en) 1997-02-21

Family

ID=23130857

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9506995A ZA956995B (en) 1994-08-22 1995-08-21 Methods of reducing scarring in wound healing.

Country Status (14)

Country Link
US (1) US5550151A (xx)
EP (1) EP0772438B1 (xx)
JP (1) JPH10504823A (xx)
AT (1) ATE179890T1 (xx)
AU (1) AU3411195A (xx)
CA (1) CA2198011A1 (xx)
DE (1) DE69509657T2 (xx)
DK (1) DK0772438T3 (xx)
ES (1) ES2131331T3 (xx)
GR (1) GR3030255T3 (xx)
IL (1) IL115023A0 (xx)
MX (1) MX9701328A (xx)
WO (1) WO1996005826A1 (xx)
ZA (1) ZA956995B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4688046B2 (ja) * 2004-11-05 2011-05-25 株式会社ポーラファルマ 肥厚性瘢痕動物モデル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
WO1996005826A1 (en) 1996-02-29
CA2198011A1 (en) 1996-02-29
EP0772438A1 (en) 1997-05-14
ES2131331T3 (es) 1999-07-16
EP0772438A4 (en) 1997-09-03
GR3030255T3 (en) 1999-08-31
JPH10504823A (ja) 1998-05-12
ATE179890T1 (de) 1999-05-15
US5550151A (en) 1996-08-27
IL115023A0 (en) 1995-12-08
EP0772438B1 (en) 1999-05-12
DK0772438T3 (da) 1999-11-01
DE69509657D1 (de) 1999-06-17
AU3411195A (en) 1996-03-14
MX9701328A (es) 1997-05-31
DE69509657T2 (de) 1999-09-30

Similar Documents

Publication Publication Date Title
ZA956986B (en) Methods of inhibiting viral replication.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
MX9709466A (es) Medicamento para inhibir el melanoma.
IL115016A0 (en) Methods for bone healing and fracture repair
MX9701333A (es) Metodos para inhibir el daño neuronal.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
AU8155094A (en) Methods of inhibiting hirsutism and alopecia in women
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
GR3030255T3 (en) Methods of reducing scarring in wound healing
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".